Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised AIP Management on the acquisition of the Överturingen wind farm
Mandate

Vinge has advised AIP Management on the acquisition of the Överturingen wind farm

October 22, 2026 M&A Environmental Law Real Estate and Construction Banking and Finance Corporate Tax

Vinge has advised AIP Management, an investor specialising in energy and climate transition infrastructure, in connection with the acquisition of an onshore wind farm in Överturingen in central Sweden.

The wind farm has a capacity of 241 MW and has been in operation since 2022. The acquisition agreement was signed in September 2026, and the transaction was completed in October 2026. As a result of this acquisition, together with the previous acquisition of the 71 MW Aldermyrberget wind farm in northern Sweden, AIP Management has established a portfolio of operational Nordic renewable energy assets totalling 312 MW. 

Vinge’s team primarily consisted of Christoffer Thalin, Agnes Tell, Johan Cederblad, Einar Dahlberg, Lisa Bourghardt, Markus Hedbys, Oscar Bengtsson Kindgren, Sofie Nordgren and Victor Ericsson.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026